Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Blood Pressure Management: Study finds change of medication twice as great as doubling the dose

A change in medication can benefit patients on blood pressure-lowering therapies significantly more than increasing the dose of their current medication.

A recent study from Uppsala University that was published in the Journal of the American Medical Association (JAMA) demonstrates this.


In this study, four different blood pressure-lowering medications were tested out on 280 individuals over the course of a year.

"The effect of a change of medication can be twice as great as the effect of doubling the dose of the patient's current medication. It was clear in our study that certain patients achieved lower blood pressure from one drug than from another. This effect is large enough to be clinically relevant," said Johan Sundstrom, cardiologist and Professor of Epidemiology at Uppsala University, who is the first author of the study.

Most Swedes develop high blood pressure sooner or later; more than two million Swedes have high blood pressure at the present time.

Only a fifth of them have managed to bring their blood pressure under control through drug therapy, and some studies suggest that only half of them take their blood pressure medication as intended.

Could this be because the efficacy and side-effects of the drugs differ from individual to individual?

Given the great diversity of blood pressure drugs, there is a serious risk that patients will not receive the optimal drug at the first attempt, and that this will result in poor blood pressure lowering and unnecessary side-effects.

A new study at Uppsala University investigated whether there is an optimal blood pressure drug for each individual, and therefore a potential for personalized blood pressure treatment.

The study involved 280 patients.

All these individuals tested four different blood pressure drugs, one after the other, at several different times over a total period of one year.

Researchers saw that the effect of the treatment varied widely from individual to individual and that it was clear that certain patients achieved lower blood pressure from one drug than from another. Study's findings challenge the strategy recommended in current treatment guidelines, in which four drug groups are recommended equally warmly for all patients with high blood pressure.

"If we personalize each patient's medication, we can achieve a better effect than if we choose a drug from one of these four drug groups at random. Our study shows that given the right blood pressure drug, the patient can lower their blood pressure and as a result can probably obtain better protection against future cardiovascular diseases more quickly," Sundstrom said.

More For You

Home cervical screening kits in England

Government data states that around five million women are still not attending cervical screenings

Getty Images

Home cervical screening kits launched in England

Key Summary

  • NHS England has launched at-home cervical screening kits to improve uptake among women aged 25 to 64.
  • The discreet kits aim to overcome barriers like embarrassment and increase screening rates from 68.8 per cent towards the 80 per cent target.
  • Early diagnosis through home testing is expected to boost survival rates and help tackle cervical cancer for all communities.

NHS England has created an innovative at-home human papillomavirus (HPV) testing, for women who are yet to take cervical screening service.

Keep ReadingShow less
NHS warns doctors using unapproved  AI Software

NHS England has demanded that GPs and hospitals stop using artificial intelligence software that could breach data protection rules.

iStock

NHS warns doctors against use of unapproved AI software

Key Summary

  • NHS wants GPs and hospitals to stop using dubious artificial intelligence software during patient meetings
  • It had in April urged the doctors to use AI for notetaking using Ambient Voice Technology software
  • But it now claims that many AVT suppliers, who fail to meet NHS governance standards, are selling them to doctors
  • British Medical Association officials want the NHS to help doctors choose the safe AVT software

Doctors have been warned against the use of AI software that does not meet minimum standards to record and transcribe patient meetings.

Keep ReadingShow less
Mother holding newborn baby during early postnatal care in NHS maternity setting

Mother with newborn in NHS maternity care

Getty Images

Failing maternity services leads to nation-wide inquiry

Key Summary
  • Wes Streeting has ordered a national inquiry into failing NHS maternity and neonatal services
  • The review will start this summer, focusing first on the worst-performing units
  • A second phase will examine the entire system and propose national improvements
  • The inquiry will tackle racial inequalities and maternity mortality disparities

Health Secretary Wes Streeting has commissioned a nation-wide inquiry due to the rise in the number of failing maternity and neonatal services in the country.

NHS trusts such as Morecambe Bay, Shrewsbury and Telford, East Kent, Nottingham and Leeds are some of the names on the worst-performing list.

Keep ReadingShow less
UK globally competitive in life sciences

The Industrial Strategy has identified eight high-growth potential sectors, including life sciences.

iStock

Key test will be to make UK globally competitive in life sciences: ABPI

Key Summary

  • The Industrial Strategy has identified life sciences as one of its high-growth potential sectors
  • ABPI wants the UK to become a leading centre for life sciences research and development
  • It wants the government to move quickly from planning to delivery

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the government’s new Industrial Strategy, but said the key test for life sciences will be whether it can return the UK to international competitiveness.

Keep ReadingShow less
Screening newborn babies for rare diseases will involve sequencing their complete DNA

Screening newborn babies for rare diseases will involve sequencing their complete DNA

iStock

DNA test for all babies to study disease risk

Key Summary

  • The DNA of newborn babies will be sequenced using blood samples from their umbilical cord
  • The government will invest £650m in DNA research for all patients by 2030
  • Genomics and AI would be used for faster diagnoses

Children born in England will have their DNA mapped to screen for hundreds of diseases under the NHS plan for the next 10 years.

Keep ReadingShow less